⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BioOra Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
BioOra Limited
↗Wellington, New Zealand
BioOra is a commercial-stage biotechnology company based in New Zealand, specializing in the development and automated manufacturing of next-generation CAR T-cell therapies. Founded in 2021 as a partnership between the Malaghan Institute of Medical Research and Bridgewest Ventures NZ, the company aims to improve patient access to life-saving immunotherapies by reducing manufacturing costs and treatment times.
The company utilizes the Cocoon® automated cell therapy manufacturing platform to produce its lead candidate, Atla-cel, a third-generation CD19-directed CAR-T therapy. BioOra is currently scaling its operations with a dedicated health and technology center in Christchurch, New Zealand, and has established international partnerships to expand its reach into global markets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Private
Investors:Bridgewest Ventures NZ, Callaghan Innovation
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Cell therapy, CAR-T
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Malaghan Institute of Medical Research (Clinical development), Octane Biotech/Octane Medical Group (Cocoon® platform), Wellington Zhaotai Therapies Limited (Licensing/Global rights), Cincinnati Children's Hospital Medical Center (Pediatric B-ALL development)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
John Robson - CEO
LINKS
Website:bioora.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BioOra Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.